Most patients miss occasional doses of antihypertensive treatment. The consequent loss of blood pressure (BP) control, and thus increased cardiovascular risk, may be mitigated by prescribing "forgiving" drugs that have a duration of antihypertensive effect beyond the 24-hour dosing interval. However, the consequences of missed doses for cardiovascular outcomes, and additional impact of duration of drug action, have not been evaluated quantitatively. We developed a method to quantify the chain of factors linking adherence and duration of drug action with outcomes; an important consideration given that adherence and hence BP reduction in real-world clinical practice are typically much lower than in randomised controlled trials. The method involves simulating 256-day dosing histories for 1250 individuals, incorporating realistically distributed gaps in dosing based on a study of electronically monitored dosing records from 4783 hypertensive patients in clinical trials. Percentage adherence is adjusted by altering the proportion of doses missed while preserving a realistic distribution of gap length. Systolic BP (SBP) reduction for each patient is estimated, with rises and falls according to the individual's dosing behaviour. By averaging SBP reductions over time and individuals, population mean SBP reduction is estimated. Cardiovascular disease (CVD) risk over, for example, 10 years may then be predicted using the Framingham Risk Equation, with baseline characteristics from NHANES 2005-2006 (average data: age 65.2 years; 52.9% women; SBP 155.95 mmHg; total cholesterol 5.41 mmol/L) and baseline absolute 10-year CVD risk of 27.0%. The method allows variable inputs including adherence level (%), rate of loss of antihypertensive effect when treatment is interrupted (mmHg/day), rate of BP reduction when treatment is (re)started (mmHg/day) and SBP-lowering effect of uninterrupted treatment (mmHg). In conclusion, we describe a novel method that allows quantifi cation of the effects of treatment adherence and antihypertensive drug forgiveness on clinical outcomes (i.e. SBP and CVD risk reduction).
PCV142 AN APPLICATION OF IMPUTATION TECHNIQUES TO IMPROVE DATA AVAILABILITY FROM ELECTRONIC MEDICAL RECORDS
Exuzides A, Colby C ICON Clinical Research, San Francisco, CA, USA OBJECTIVES: Analytic data sets based on electronic Medical Records (eMRs) offer long and detailed patient follow-up, large sample sizes, and a rich set of variables. However, the existence of a particular variable within an eMR is no assurance of actual data availability for all patients. Patients may receive lab tests irregularly or miss visits. Reporting standards can vary within an eMR system, creating large numbers of patients with missing data. We present details from a three step imputation process to improve eMR data availability from an observational study of hypertension outcomes. METHODS: We used an analytic data set comprised of 227,257 patients from 10 participating medical centers. One important element of the study was the computation of a cardiovascular risk score based on 11 demographic and clinical variables available from eMRs. However, only 43,676 patients (19%) had complete data for all 11 variables. To increase the sample size of patients with complete data for all 11 variables, we used three imputation techniques: we fi rst allowed for lab and blood pressure values to be carried forward to replace missing values; we then augmented a missing diabetes status with pharmacy data by using diabetes-specifi c medications to indicate a positive diabetes history; and, fi nally, we applied a multiple imputation (MI) technique, based on a Markov Chain Monte Carlo (MCMC) approach, implemented using SAS ® PROC MI. RESULTS: After application of the three data imputation techniques, the sample size of patients with complete or imputed data for all 11 variables increased to 75,209 (33%) . This amounts to a substantial increase (72%) in the number of patients with all critical variables available to be used for further analysis. CONCLUSIONS: Proper application of imputation techniques, including MI, can yield a substantial increase in the number of patients available for analysis. IgG serologic tests in the diagnosis of celiac disease including anti-tissue transglutaminase (tTG) antibody, anti-deamidated gliadin peptide antibody (DGP), anti-endomysial antibody (EMA), and anti-gliadin antibodies (AGA). METHODS: A systematic review of the peer-reviewed literature was conducted to identify studies that evaluated the sensitivity and specifi city of serologic celiac disease tests using small bowel biopsy as the gold standard. The patient population consisted of untreated, undiagnosed subjects with symptoms consistent with the disease. Pooled estimates of sensitivity and specifi city were calculated using a bivariate, binomial generalized linear mixed model (SAS 9.2) which takes into account the negative correlation between sensitivity and specifi city. Statistical signifi cance was defi ned by p-values less than 0.05, where "false discovery rate" adjustments were made for multiple hypothesis testing. RESULTS: In total, 17 studies were eligible for the analysis. The pooled analysis showed that IgA tTG has a sensitivity of 92.1% (95% CI 88.0, 96.3), compared to 89.2% (83.3, 95.1, p = 0.12) for IgA DGP, 85.1% (79.5, 94.4 , p = 0.07) for IgA EMA, 74.9% (63.6, 86.2, p = 0.0003) for IgA AGA. Combining more than one serologic test slightly increased the sensitivity, 95.1% (92.2, 98%, p = 0.039 vs. IgA tTG). The pooled sensitivity of IgG DGP was 88.4% (95% CI: 82.1, 94.6), 44.7% (30.3, 59.2, p = 0.0003) for IgG tTG, and 69.1% (56.0, 82.2, p = 0.34) for IgG AGA. Specifi city ranged from 90.1% to 93.9% and was similar among the different tests. The quality of the evidence according to the GRADE Working Group criteria was considered "moderate" for IgA tTG and EMA, "low" for IgA DGP and test combinations, and "very low" for IgA AGA. CONCLUSIONS: The evidence available suggests that IgA tTG has a higher accuracy than other serologic tests. Combining more than one serologic test contributes little to the diagnostic accuracy. Until recently, few head-to-head trials evaluated the effi cacy of peginterferon-alpha-2a versus peginterferon-alpha-2b and none meta-analysis was available so far. In 2010, a meta-analysis performed by Awad et al was able to demonstrate that peginterferon-alpha-2a was more effi cacious in achieving sustained virological response as compared to peginterferon-alpha-2b. McHutchison 2009, one of the studies included in the meta-analysis, evaluated two different doses of peginterferonalpha-2b (standard-dose: 1,5 mcg/kg; low-dose: 1,0 mcg/kg), raising doubts about possible negative impact of lower dose on the analysis results.We aim to compare treatment outcomes in genotypes 1/4 HCV infection treated with peginterferon-alpha-2a versus peginterferon-alpha-2b at standard-dose (per package insert) both plus ribavirin in order to assess effi cacy, performing a systematic review and meta-analysis of published randomized controlled trials (RCTs). METHODS: An extensive search through main medical information databases (MEDLINE, Cochrane Library, Embase and Lilacs) and specialized websites was conducted on the second trimester of 2010. We aim to indentify RCTs which evaluate treatment effi cacy of peginterferon-alpha-2a versus standard-dose peginterferon-alpha-2b both plus ribavirin for HCV treatment in genotypes 1/4 patients not co-infected with HIV. According to heterogeneity test, a fi xed or a random-effect model was adopted. RESULTS: Only 6 papers out of 623 found (databases citation without duplicates plus manual searches) met our inclusion criteria: 1)Ascione, 2009; 2)Rumi, 2009; 3)McHutchison, 2009; 4)Yenice, 2006; 5) Scotto, 2008; 6)Berak, 2007. For genotypes 1/4 chronic HCV infection patients, peginterferon-alpha-2a showed higher SVR as compared to standard dose of peginterferon-alpha-2b: 42.09% versus 33.44% (RR = 1.10, IC 95% 1.006-1.202, assuming a fi xed-effect framework). CONCLUSIONS: According to these results, no signifi cant impact on already published meta-analysis results was observed when lower dose peginterferon-alpha-2b patients were excluded from the analysis. In summary, peginterferon-alpha-2a is more effective in treating genotypes 1/4 HCV infected patients as compared to standard-dose peginterferon-alpha-2b, both in association with ribavirin. Pouchitis is the most frequent long-term complication of ileal pouchanal anastomosies (IPAA) surgery for ulcerative colitis (UC) which is a nonspecifi c infl ammation of the ileal reservoir. Its clinical frequency varies depending on the defi nition and the follow up but is approximately 50% after a decade. Antibiotics and probiotics are currently the most widely accepted treatment in pouchitis patients. Objective of this study was to meta-analyze effi cacy of probiotics and antibiotics in the management of pouchitis. METHODS: All databases specially Pubmed, Web of Science, Scopus, Cochrane, and Google Scholar were searched between 1965 and December 2009, and relevant controlled clinical trials were extracted, reviewed, and validated according to the study protocol. The outcome of interest was defi ned by a pouchitis disease activity index (PDAI) < 7. Thirteen clinical trials were included in the meta-analysis. RESULTS: Pooling of the results from eight trials yielded a relative risk (RR) of 5.33 with a 95% CI of 2.12-13.35 and a signifi cant RR (P = 0.0004) in the treatment group in comparison with the placebo group. Summary RR for clinical improvement in 6 trials was 14.17 with a 95% CI of 1.19-168.93 (P = 0.036) in 13th Euro Abstracts A369 effi cacy of VSL#3 (all doses) comparing to placebo and slightly more effective for VSL#3 (6 g/day) comparing to placebo with RR of 20.35 with a 95% CI of 6.16-67.22 (P < 0.0001). Effi cacy of antibiotics comparing to placebo showed a summary RR of 2.68 with a 95% CI of 0.4-17.99 and P = 0.3107 for clinical improvement in three trials. The summary RR for effi cacy of ciprofl oxacin comparing to metronidazole was 0.68 with a 95% CI of 0.44-1.06 (P = 0.8913). CONCLUSIONS: In conclusion, alongside the benefi t of probiotics and antibiotics in the management of pouchitis, effects of probiotics and antibiotics on pouchitis vary according to different mixtures of microorganisms strains in probiotics and different spectrums of antibiotics.
GASTROINTESTINAL DISORDERS -Clinical Outcomes Studies

PGI1 A SYSTEMATIC REVIEW OF THE DIAGNOSTIC ACCURACY OF SEROLOGIC TESTS IN THE DIAGNOSIS OF CELIAC DISEASE
PGI2
IS THERE ANY DIFFERENCE BETWEEN THE EFFECTS OF THERAPY WITH PEGINTERFERON-ALPHA-2A VERSUS STANDARD-DOSE PEGINTERFERON-ALPHA-2B? A META-ANALYSIS COMPARING BOTH TREATMENTS PLUS RIBAVIRIN IN GENOTYPE 1/4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION PATIENTS
PGI3 EFFICACY OF ANTIBIOTICS AND PROBIOTICS IN MANAGEMENT OF POUCHITIS; A META-ANALYSIS
PGI4 PREVALENCE AND INCIDENCE OF HEPATITIS A IN A UNITED STATES MANAGED CARE CLAIMS DATABASE
Changolkar AK 1 , Eisenberg D 2 , Misurski DA 1 1 GlaxoSmithKline, Philadelphia, PA, USA; 2 HealthCore, Wilmington, DE, USA OBJECTIVES: To evaluate the prevalence and incidence of hepatitis a in a managed care population, segmented by a range of characteristics including age, gender, geography, and health insurance plan. METHODS: This was an observational retrospective cohort study utilizing medical and pharmacy claims data for January 1, 2005 through December 31, 2008 from the Impact National Managed Care Database (Benchmark Database). The index date was defi ned as the date of the fi rst and only diagnostic claim for hepatitis a within the intake period. All prevalence results reported below are per 100,000 and incidence is presented as per person years. RESULTS: Out of a total of 94,985,124 subjects in the database, females and males were represented equally (51% and 49% respectively). The 45-64 year age group had the greatest percentage of subjects. The prevalence of hepatitis a among men and women were almost equal (9 and 8, respectively). The 45-54 years age group had the highest hepatitis a prevalence (4) followed by the 25-34, 35-44, and 55-64 age groups (3 for each group). The largest hepatitis a prevalence rate was from the northeast region (7) followed by the south (6). In the 2005-2008 timeframe, hepatitis a prevalence was similar in each year (4). Incidence rates across age, region and specifi c zip codes in person years were less than 1 person per year. The incidence was slightly higher in males. Among three digit zip codes, the zip codes "100" showed higher incidences each year with higher prevalence. CONCLUSIONS: In a large commercially insured US population, we observed similar prevalence rates of hepatitis a for males and females. The disease was most prevalent in the 45-54 years age group. The northeast had the highest prevalence rate from 2005-2008.
GASTROINTESTINAL DISORDERS -Cost Studies
PGI5 A BUDGET IMPACT ANALYSIS OF THE HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON IN BRAZIL
Fonseca M, Araújo GTBD AxiaBio, São Paulo, Brazil OBJECTIVES: Cost-effectiveness analyses of new hepatitis C drugs have been used to select and approve drugs that should be fi nanced by the public health care system. However there are still a huge amount of uncertainties within these studies. The fact of having pharmacoeconomic and budget impact data of these new pharmacological alternatives will help to select the most effi cient alternative. With this, the objective is to perform a budget impact analysis (BIA) of the treatment with pegylated interferon (pegIFN), alfa-2a or alfa-2b, plus ribavirin in, economically active genotype I patients, aging from 30 to 59 years, with chronic hepatitis C (CHC). METHODS: An interactive model has been designed from the inputs obtained from the medical literature. Both strategies have been considered as therapeutic equivalents, without signifi cative difference in side effects, and as having the same price. RESULTS: The number of patients with CHC evaluated in the model has been of 355,611, 15.2% between 30 and 39 years, 13% between 40 and 49 years and 9% between 50 and 59 years, mimicking the Brazilian population and with an average weight of 70.6 kg. The duration of treatment was 48 weeks, with virologic response measured in weeks 2.4,12.24 and 48. a total of 91% and 99.8% of the patients receiving pegIFN alfa-2a or alfa-2b, respectively achieved sustained virological response at 72 weeks. Total cost was R$ 4,012,531,131.29 and R$3,752,238,973.99 for the treatment with pegIFN alfa-2a + RIB and pegIFN alfa-2b + RIB, respectively. CONCLUSIONS: Although cost-effectiveness analysis appears to be favorable to pegIFN alfa-2a + RIB, a BIA seems to favour pegIFN alfa-2b + RIB due to its better predictability in the 12 nd week of treatment. In this case, the treatment with pegIFN alfa-2b + RIB (in comparison with pegIFN alfa-2a + RIB) is an effi cient strategy.
PGI6
COST-EFFECTIVENESS OF MR ELASTOGRAPHY FOR DIAGNOSING LIVER FIBROSIS: PRELIMINARY THRESHOLD ASSESSMENT
Lee DW 1 , Palathinkara V 1 , Dekoven M 2 1 GE Healthcare, Waukesha, WI, USA; 2 IMS Health, Falls Church, VA, USA OBJECTIVES: MR Elastography (MRE) is a non-invasive test under clinical trial evaluation for effectiveness in helping diagnose liver fi brosis. This study estimated the accuracy needed for MRE to be cost-neutral from a US payer's perspective.
METHODS:
We constructed a decision-analytic model comparing diagnostic costs under two scenarios for patients with suspected liver fi brosis: 1) biopsy, or 2) MRE followed by biopsy when the MRE test was positive. We conducted a targeted litera-ture review and consulted with a leading hepatologist and pathologist to identify the appropriate procedure codes associated with liver biopsy; we assumed MRE would be reimbursed using CPT-4 code 74,181 (magnetic resonance (eg., proton) imaging, abdomen; without contrast material(s)). We assigned the appropriate allowable charges to the identifi ed procedure codes using the 2010 Medicare Physician Fee Schedule. Finally, we assumed negative predictive values (NPV) of 0.8, 0.9 and 0.95, and that patients with a false-negative MRE ultimately received a biopsy. RESULTS: The cost of a liver biopsy was $1424 (ultrasound $164, surgical $881, pathology $347, laboratory $32) and the cost of an MRE (without contrast) was $946 (hospital setting) or $666 (non-hospital setting). In a hospital setting, MRE is potentially cost saving if the test-negative rate is greater than 83%, 74% and 70% for NPVs of 0.8, 0.9 and 0.95, respectively. In a non-hospital setting, MRE can reduce diagnostic costs when more than 58%, 52% and 49% or patients have negative MRE results for the corresponding NPV values. CONCLUSIONS: The cost of liver biopsy is substantial as compared to MRE. MRE offers the potential of reducing the cost of diagnosing liver fi brosis by avoiding unnecessary biopsies. Cost saving potential increases with MRE's negative predictive value and negative test rate.
PGI7 ECONOMIC BURDEN OF OPIOID INDUCED CONSTIPATION IN SPAIN
Guijarro P 1 , Alonso-Babarro A 2 , Viqueira A 1 , Fernandez G 1 1 Pfi zer Spain, Alcobendas, Madrid, Spain; 2 La Paz Hospital, Madrid, Spain OBJECTIVES: To analyze the use of health care resources and the associated costs in patients with opioid induced constipation (OIC). METHODS: An observational, retrospective, multicenter study was carried out in Spanish National Health System hospitals. All patients were free of constipation at baseline and received opioids for at least 2 months. In order to determine patient resource utilization, a review of the patient records and patient-interviews were performed to all patients diagnosed with OIC. Patients were evaluated depending on response to oral treatment for OIC. The observation period was 2 months. The unit costs were obtained from Spanish databases (c 2009). RESULTS: A total of 744 patients were included. Patients had a mean (SD) age of 64.2 (13.4) and 48% were male. During the study period, 46.6% of the patients developed OIC. Most of these were treated fi rst with oral laxatives exclusively (67.7%), 63.8% responded to the treatment and 36.2% did not. Of the total number of patients with OIC, 61.5% required a visit to health care services. Forty-four patients required a visit to the Emergency Room (ER) and 26 were hospitalized with a median length of stay of 3 days. Overall mean total cost (SD) of constipation management was c271.08 (c621.22). Resource utilization in responders to oral laxatives was statistically signifi cant lower than in non-responders. a higher percentage of non-responders required health care visits, ER visits, and hospitalizations (P < 0.001). The mean cost (SD) for each responder was c115 (c230) compared to c442 (c810) for each non-responder (P < 0.001). CONCLUSIONS: OIC increases health care resource utilization particularly in patients with a poor response to oral laxatives. The economic burden of OIC was 3.8 times higher in non-responders than in responders.
PGI8 HIDDEN COSTS OF ROTAVIRUS DISEASE-A RETROSPECTIVE MATCHED ANALYSIS OF HOSPITAL EPISODE STATISTICS (HES) DATA
Morgan C 1 , Adlard NE 2 , Carroll SM 2 1 Cardiff Research Consortium Ltd, CARDIFF, UK; 2 Sanofi Pasteur MSD, Maidenhead, UK OBJECTIVES: To determine the impact of rotavirus (RV) disease as a secondary diagnosis on hospital length of stay (LOS) and cost for children under fi ve years of age in England. METHODS: The study was based on Hospital Episodes Statistics for England 2001-2007 using a matched cohort design. Admissions with a secondary diagnosis of RV were extracted and matched by age, year of admission and, where relevant, therapeutic procedure, to other admissions from HES with the same primary diagnosis. Primary admissions were classifi ed as potentially related or unrelated to RV. LOS was compared using the paired Wilcoxon test. RESULTS: Of 2126 admissions with a secondary diagnosis of RV, 707 (33.3%) had no other secondary diagnoses. Of these, 385 admissions were matched for primary diagnosis to controls. Median LOS for admissions was 2.0 days (Inter-Quartile Range [IQR] 1.0-4.0), mean (sd) 3.2 (4.1) compared with median 1.0 (IQR 0.0-1.5), mean 1.4 (sd 3.5) for control admissions (p-value < 0.001). Median cost/admission was £771 (IQR £604-£1090), mean cost was £1105 (sd £1064) compared with median £650 (IQR £564-£1090), £902 (sd 1004) (p-value < 0.001). a total of254/385 admissions were defi ned as unrelated to RV. For these admissions, median LOS was 2.0 days (IQR 1.0-4.25), mean 3.7 (sd 4.5) compared with median 1.0 (IQR 0.0-2.0), mean 1.6 (sd 4.0) for control admissions (p-value < 0.001). Median cost/admission was £918 (IQR £564-£1090), mean £1132, (sd £1132) compared with median £771 (IQR £564-£1090), mean £980 (sd £1187), (p-value < 0.001). CONCLUSIONS: As a secondary diagnosis in HES, RV has a signifi cant incremental impact on LOS and cost. Variations in testing and reporting of RV mean that HES data may signifi cantly under represent the overall burden of RV disease. This implies that standard modelling methodologies may underestimate the true burden of RV disease in the context of health care acquired infection.
